DelveInsight’s “Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroesophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Gastroesophageal Adenocarcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Adenocarcinoma Market Forecast
Some of the key facts of the Gastroesophageal Adenocarcinoma Market Report:
-
The Gastroesophageal Adenocarcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In June 2024, Arcus Biosciences has completed patient enrollment for the Phase III STAR-221 clinical trial, which evaluates the combination of domvanalimab and zimberelimab with chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (upper GI cancers). Domvanalimab is an Fc-silent anti-TIGIT antibody, while zimberelimab is an anti-PD-1 monoclonal antibody. Both therapies are currently under investigation.
-
In 2023, the total number of incident cases of gastroesophageal adenocarcinoma exceeded 220,000 across the 7MM.
-
In 2023, Japan recorded the highest number of incident cases of gastroesophageal adenocarcinoma among the 7MM.
-
In the US, Stage IV had the highest number of incident cases of gastroesophageal adenocarcinoma, whereas Japan reported the most cases in Stage I.
-
Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.
-
Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others
-
The Gastroesophageal Adenocarcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Adenocarcinoma pipeline products will significantly revolutionize the Gastroesophageal Adenocarcinoma market dynamics.
Gastroesophageal Adenocarcinoma Overview
Gastroesophageal adenocarcinoma is a type of cancer that arises from the glandular cells lining the esophagus and the stomach. It is characterized by the abnormal growth of these cells, which can lead to the formation of tumors. This cancer often develops at the junction of the esophagus and stomach (gastroesophageal junction) and is associated with risk factors such as obesity, gastroesophageal reflux disease (GERD), smoking, and a diet low in fruits and vegetables. Symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn. Diagnosis typically involves imaging tests, endoscopy, and biopsy. Treatment options may include surgery, chemotherapy, radiation therapy, or targeted therapies, depending on the cancer's stage and the patient’s overall health.
Get a Free sample for the Gastroesophageal Adenocarcinoma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/gastroesophageal-adenocarcinoma-market
Gastroesophageal Adenocarcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Gastroesophageal Adenocarcinoma Epidemiology Segmentation:
The Gastroesophageal Adenocarcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Gastroesophageal Adenocarcinoma
-
Prevalent Cases of Gastroesophageal Adenocarcinoma by severity
-
Gender-specific Prevalence of Gastroesophageal Adenocarcinoma
-
Diagnosed Cases of Episodic and Chronic Gastroesophageal Adenocarcinoma
Download the report to understand which factors are driving Gastroesophageal Adenocarcinoma epidemiology trends @ Gastroesophageal Adenocarcinoma Epidemiology Forecast
Gastroesophageal Adenocarcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Adenocarcinoma market or expected to get launched during the study period. The analysis covers Gastroesophageal Adenocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastroesophageal Adenocarcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Gastroesophageal Adenocarcinoma Therapies and Key Companies
-
KEYTRUDA (pembrolizumab): Merck
-
LONSURF (trifluridine/ tipiracil): Taiho Pharmaceuticals
-
Sacituzumab Tirumotecan (MK-2870): Merck/Sichuan Kelun-Biotech
-
Evorpacept (ALX148): ALX Oncology
-
Paclitaxel: Canadian Cancer Trials Group
-
Trifluridine-Tipiracil: Merck Sharp & Dohme LLC
-
ASKB589: AskGene Pharma, Inc.
-
AK104: Akeso
-
OBP-301: Weill Medical College
-
tucatinib: Seagen Inc.
-
Docetaxel for injection (Albumin-bound): CSPC ZhongQi Pharmaceutical
-
Zanidatamab: Jazz Pharmaceuticals
-
Trastuzumab deruxtecan: Daiichi Sankyo
-
Capecitabine: RemeGen Co., Ltd.
-
Infigratinib: LianBio LLC
-
Atezolizumab: Hoffmann-La Roche
-
Bemarituzumab: Amgen
-
PT886: Phanes Therapeutics
Discover more about therapies set to grab major Gastroesophageal Adenocarcinoma market share @ Gastroesophageal Adenocarcinoma Treatment Landscape
Gastroesophageal Adenocarcinoma Market Drivers
-
Increasing Incidence Rates
-
Advancements in Treatment
-
Improved Diagnostic Techniques
-
Aging Population
-
Rising Awareness
-
Clinical Trials and Research
Gastroesophageal Adenocarcinoma Market Barriers
-
High Treatment Costs
-
Limited Early Detection
-
Side Effects of Treatment
-
Drug Resistance
-
Regulatory Hurdles
-
Geographical Disparities
Scope of the Gastroesophageal Adenocarcinoma Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others
-
Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others
-
Gastroesophageal Adenocarcinoma Therapeutic Assessment: Gastroesophageal Adenocarcinoma current marketed and Gastroesophageal Adenocarcinoma emerging therapies
-
Gastroesophageal Adenocarcinoma Market Dynamics: Gastroesophageal Adenocarcinoma market drivers and Gastroesophageal Adenocarcinoma market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Gastroesophageal Adenocarcinoma Unmet Needs, KOL’s views, Analyst’s views, Gastroesophageal Adenocarcinoma Market Access and Reimbursement
To know more about Gastroesophageal Adenocarcinoma companies working in the treatment market, visit @ Gastroesophageal Adenocarcinoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Gastroesophageal Adenocarcinoma Market Report Introduction
2. Executive Summary for Gastroesophageal Adenocarcinoma
3. SWOT analysis of Gastroesophageal Adenocarcinoma
4. Gastroesophageal Adenocarcinoma Patient Share (%) Overview at a Glance
5. Gastroesophageal Adenocarcinoma Market Overview at a Glance
6. Gastroesophageal Adenocarcinoma Disease Background and Overview
7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastroesophageal Adenocarcinoma
9. Gastroesophageal Adenocarcinoma Current Treatment and Medical Practices
10. Gastroesophageal Adenocarcinoma Unmet Needs
11. Gastroesophageal Adenocarcinoma Emerging Therapies
12. Gastroesophageal Adenocarcinoma Market Outlook
13. Country-Wise Gastroesophageal Adenocarcinoma Market Analysis (2020–2034)
14. Gastroesophageal Adenocarcinoma Market Access and Reimbursement of Therapies
15. Gastroesophageal Adenocarcinoma Market Drivers
16. Gastroesophageal Adenocarcinoma Market Barriers
17. Gastroesophageal Adenocarcinoma Appendix
18. Gastroesophageal Adenocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Guarav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
